| PSD | particle size distribution; peptone, starch, and dextrose; periodic synchronous discharge; phase-sen... |
|---|---|
| UDR-BMD | ultradistal radius bone mineral density |
| OHA | Oral Hypoglycemic Agents |
| CTA | Canadian Tuberculosis Association; chemotactic activity; chromotropic acid; Committee on Thrombolyti... |
| ICAAC | Interscience Conference on Antimicrobial Agents and Chemotherapy |
| either particle flux density | The particle fluence rate, or energy flux density, the energy fluence rate of intensity. Compare: fluence. (05 Mar 2000) |
|---|---|
| familial high density lipoprotein deficiency | Familial high {density lipoprotein deficiency}; a heritable disorder of lipid metabolism characterised by almost complete absence from plasma of high density lipoproteins, and by storage of cholesterol esters in foam cells, tonsillar enlargement, an orange or yellow-gray colour of the pharyngeal and rectal mucosa, hepatosplenomegaly, lymph node enlargement, corneal opacity, and peripheral neuropathy; autosomal recessive inheritance. Synonym: familial high {density lipoprotein deficiency}, Tangier disease. Origin: G. An-, priv., + alpha, a, + lipoprotein + -aemia, blood (05 Mar 2000) |
| flux density | <radiobiology> Total amount of a quantity passing through a unit surface area in unit time See: flux. (09 Oct 1997) |
| low density lipoprotein | <biochemistry> A lipoprotein substances (combination of a fat and a protein) which acts as a carrier for cholesterol and fats in the bloodstream. High levels of low density lipoprotein are considered a positive risk factor for the development of coronary artery disease. Less than 130 mg/dl is desirable, 130 to 159 mg/dl is borderline high, over 160 is considered high. Acronym: LDL (10 Jan 1998) |
| low density lipoprotein receptor | <biochemistry> A cell surface protein that mediates the endocytosis of low density lipoprotein by cells. Genetic defects in low density lipoprotein receptors lead to abnormal serum levels of low density lipoprotein and hypercholesterolaemia. (16 Mar 1998) |
| low-density lipoprotein receptors | Receptors on the surface of cells, especially liver cells, which bind to low density lipoprotein and promote clearance of LDL from the plasma. (05 Mar 2000) |
| bone within a bone | <radiology> STOP heavy metal, S: sickle cell disease, T: Thorotrast, O: osteopetrosis, P: Paget's disease, heavy metals, hypervitaminosis D (12 Dec 1998) |
| abortifacient agents | Chemical substances that interrupt pregnancy after implantation. (12 Dec 1998) |
| abortifacient agents, non-steroidal | Non-steroidal chemical compounds with abortifacient activity. (12 Dec 1998) |
| abortifacient agents, steroidal | Steroidal compounds with abortifacient activity. (12 Dec 1998) |
| adrenergic agents | Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters. (12 Dec 1998) |
| alkylating agents | Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agent, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases. (12 Dec 1998) |
| anti-allergic agents | Agents that are used to treat allergic reactions. most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (12 Dec 1998) |
| anti-allergic and respiratory system agents | A collective term for drugs used to treat allergic reactions as well as those drugs that produce an effect on the respiratory system. (12 Dec 1998) |
| anti-anxiety agents | Agents that alleviate anxiety, tension, and neurotic symptoms, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. Some are also effective as anticonvulsants, muscle relaxants, or anaesthesia adjuvants. Adrenergic beta-antagonists are commonly used in the symptomatic treatment of anxiety but are not included here. Substances with a benzodiazepine ring structure widely used to treat anxiety and neuroses. Drugs in this class also generally have sedative or weak hypnotic properties and may be effective as muscle relaxants, anticonvulsants, and anaesthesia adjuvants. (12 Dec 1998) |